Gene therapy for
advanced coronary artery disease

XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.

Latest News

Press Release: May 2, 2024
XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions
More >>

See Our Pipeline

XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>

Research & Development

XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>